Eli Lilly and Novo Nordisk Near Agreement with White House to Lower Obesity Drug Prices
Just the facts

Eli Lilly and Novo Nordisk Near Agreement with White House to Lower Obesity Drug Prices

Summary

Eli Lilly and Novo Nordisk are reportedly close to finalizing a deal with the White House to reduce the monthly cost of their obesity medications to $149, potentially expanding Medicare coverage for these treatments.

Eli Lilly and Novo Nordisk are reportedly nearing an agreement with the White House to lower the monthly price of their obesity medications to $149, according to sources familiar with the negotiations. This initiative aims to expand Medicare coverage for these treatments, potentially making them more accessible to millions of Americans.

The deal is expected to be announced as early as Thursday, with President Donald Trump anticipated to highlight the agreement as part of his administration's ongoing efforts to reduce drug prices.

Currently, Medicare covers Novo Nordisk's Ozempic and Wegovy for diabetes treatment and Eli Lilly's Zepbound for sleep apnea, but not for weight loss. The proposed agreement would extend coverage to include obesity treatments, addressing a significant public health concern.

White House spokesman Kush Desai stated, "Discussion about deals that have not been officially announced by the Administration should be regarded as speculation."

This development is part of the administration's broader "Most Favored Nation" initiative, which seeks to align U.S. drug prices with those in other developed countries. Previous agreements under this initiative have been reached with pharmaceutical companies such as Pfizer and AstraZeneca.

The anticipated agreement with Eli Lilly and Novo Nordisk represents a significant step in the administration's efforts to make prescription drugs more affordable and accessible to the American public.

Source

CNN

Keep reading — for free

Create a free account to follow the news. No card required.